{"id":48175,"date":"2022-09-09T17:01:53","date_gmt":"2022-09-09T15:01:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/"},"modified":"2022-09-09T17:01:53","modified_gmt":"2022-09-09T15:01:53","slug":"tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/","title":{"rendered":"Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022"},"content":{"rendered":"<div>\n<p>CHICAGO&#8211;(BUSINESS WIRE)&#8211;Tempus, a leader in artificial intelligence and precision medicine, today announced three abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2022, which convenes in Paris, France from September 9-13, 2022. Tempus is presenting all three abstracts, including one oral presentation and two poster presentations.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220909005352\/en\/566718\/5\/black_wordmark.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220909005352\/en\/566718\/21\/black_wordmark.jpg\"><\/a><\/p>\n<p>\n\u201cAs we continue to expand our comprehensive precision oncology solutions for clinical use in Europe, we are thrilled to be presenting research for the first time at ESMO this year,\u201d said James L. Chen, MD, Senior Vice President of Cancer Informatics at Tempus. \u201cThis year\u2019s abstracts showcase Tempus\u2019 deep molecular profiling capabilities, including our use of AI-driven diagnostic tests, to inform data-driven patient care.\u201d\n<\/p>\n<p>\nThis year, Tempus will share a few of its latest scientific and clinical research findings via oral discussion and poster presentations, including:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Poster Presentation (923P)<\/b>: Molecular classification of cancers of unknown primary expands and refines treatment options<\/p>\n<ul class=\"bwlistcircle\">\n<li>\n<b>Session Date &amp; Time<\/b>: September 11, 2022\n<\/li>\n<li>\n<b>Location<\/b>: Poster Area, Hall 4, Paris Expo Porte de Versailles\n<\/li>\n<li>\n<b>Overview<\/b>: In this retrospective study, Tempus\u2019 Tumor Origin (TO) AI-driven algorithmic test \u2013 which uses tumor RNA expression results to predict the patient\u2019s most likely cancer type from 68 possible diagnoses \u2013 was shown to provide meaningful data that would have affected physicians\u2019 treatment decision-making for patients with cancer of unknown primary (CUP). In a study of 289 patients, 81% of patients with CUP would have their treatment informed by TO tumor classification, ultimately expanding the treatment options for CUP patients.\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<b>Oral Discussion (1529MO)<\/b>: The genomic landscape of small cell lung cancer in never smoking patients<\/p>\n<ul class=\"bwlistcircle\">\n<li>\n<b>Session Date &amp; Time<\/b>: September 12, 2022\n<\/li>\n<li>\n<b>Location<\/b>: 7.3.O, Orl\u00e9ans Auditorium, Paris Expo Porte de Versailles\n<\/li>\n<li>\n<b>Overview<\/b>: Tempus conducted a retrospective analysis of de-identified records from small cell lung cancer patients who reported \u201cnever smoking\u201d or \u201ccurrent\/former smoking\u201d status who underwent comprehensive genomic profiling with the Tempus xT assay. It was determined that \u201cnever smoking\u201d patients were more likely to harbor mutations in oncogenic drivers (e.g., EGFR and PIK3CA) and exhibited lower tumor mutational burden (TMB) and immune cell infiltration than \u201ccurrent\/former smoking\u201d patients. Ultimately, this study found that the genomic landscape of non-smokers with small cell lung cancer significantly differs from that of smokers with small cell lung cancer.\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<b>Poster Presentation (1107P)<\/b>: BRAF mutations and fusions in a real-world cohort of non-small cell lung cancer patients<\/p>\n<ul class=\"bwlistcircle\">\n<li>\n<b>Session Date &amp; Time<\/b>: September 12, 2022\n<\/li>\n<li>\n<b>Location<\/b>: Poster Area, Hall 4, Paris Expo Porte de Versailles\n<\/li>\n<li>\n<b>Overview<\/b>: Tempus retrospectively analyzed de-identified records from 6,511 patients with non-small cell lung cancer (NSCLC) that underwent comprehensive genomic profiling with the Tempus xT assay for BRAF Class I\/II\/III\/other\/unclassified mutations. This study found that the prevalence of specific biomarkers varied by class of BRAF mutation, including EGFR, KRAS, and NF1, ultimately determining that the genomic profiles of patients with BRAF alterations are distinct by class of the variant.\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n<b>About Tempus<\/b>\n<\/p>\n<p>\nTempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world\u2019s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tempus.com%2F&amp;esheet=52880043&amp;newsitemid=20220909005352&amp;lan=en-US&amp;anchor=tempus.com&amp;index=1&amp;md5=5f114aa5841067e46d6131623d769e9f\" rel=\"nofollow noopener\" shape=\"rect\">tempus.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nErin Carron<br \/>\n<br \/>Senior Director of Communications<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x65;&#x72;&#105;n&#x2e;&#x63;&#97;r&#x72;&#x6f;&#110;&#64;&#x74;&#101;&#109;p&#x75;&#115;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x65;&#114;&#105;n&#x2e;&#x63;&#97;r&#x72;&#x6f;&#110;&#64;t&#x65;&#109;&#112;u&#x73;&#x2e;&#99;o&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>CHICAGO&#8211;(BUSINESS WIRE)&#8211;Tempus, a leader in artificial intelligence and precision medicine, today announced three abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2022, which convenes in Paris, France from September 9-13, 2022. Tempus is presenting all three abstracts, including one oral presentation and two poster presentations. \u201cAs we continue to &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48175","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CHICAGO&#8211;(BUSINESS WIRE)&#8211;Tempus, a leader in artificial intelligence and precision medicine, today announced three abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2022, which convenes in Paris, France from September 9-13, 2022. Tempus is presenting all three abstracts, including one oral presentation and two poster presentations. \u201cAs we continue to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-09T15:01:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220909005352\/en\/566718\/21\/black_wordmark.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022\",\"datePublished\":\"2022-09-09T15:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/\"},\"wordCount\":603,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005352\\\/en\\\/566718\\\/21\\\/black_wordmark.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/\",\"name\":\"Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005352\\\/en\\\/566718\\\/21\\\/black_wordmark.jpg\",\"datePublished\":\"2022-09-09T15:01:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005352\\\/en\\\/566718\\\/21\\\/black_wordmark.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005352\\\/en\\\/566718\\\/21\\\/black_wordmark.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/","og_locale":"en_US","og_type":"article","og_title":"Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022 - Pharma Trend","og_description":"CHICAGO&#8211;(BUSINESS WIRE)&#8211;Tempus, a leader in artificial intelligence and precision medicine, today announced three abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2022, which convenes in Paris, France from September 9-13, 2022. Tempus is presenting all three abstracts, including one oral presentation and two poster presentations. \u201cAs we continue to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-09T15:01:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220909005352\/en\/566718\/21\/black_wordmark.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022","datePublished":"2022-09-09T15:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/"},"wordCount":603,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220909005352\/en\/566718\/21\/black_wordmark.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/","url":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/","name":"Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220909005352\/en\/566718\/21\/black_wordmark.jpg","datePublished":"2022-09-09T15:01:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220909005352\/en\/566718\/21\/black_wordmark.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220909005352\/en\/566718\/21\/black_wordmark.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tempus-announces-three-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48175"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48175\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}